| Symbol | ANIX |
|---|---|
| Name | ANIXA BIOSCIENCES INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA 95118 |
| Telephone | 408-708-9808 |
| Fax | — |
| — | |
| Website | https://www.anixa.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000715446 |
| Description | Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixas therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Companys vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against retired proteins that have been found to be expressed in certain forms of cancer. Additional info from NASDAQ: |
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Read moreAnixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Read moreAnixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Read moreAnixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Read moreAnixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Read moreAnixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Read moreAnixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Read moreAnixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Read moreDirector Baskies Arnold M 🟡 adjusted position in 5.4K shares (1 derivative) of Anixa Biosciences Inc (ANIX) at $3.46 Transaction Date: Jul 27, 2026 | Filing ID: 035122
Read moreDirector KUMAR AMIT 🟢 acquired 5.0K shares of Anixa Biosciences Inc (ANIX) at $3.44 Transaction Date: Jul 27, 2026 | Filing ID: 034952
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05316129 | Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent O… | Phase1 | Ovarian Cancer | Recruiting | 2022-04-28 | 2029-05-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Zymosan | Other | Phase EARLY_PHASE1 | Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04674306 |
| α-lactalbumin vaccine | Other | Phase EARLY_PHASE1 | Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04674306 |
| Follicle Stimulating Hormone Receptor T Cells | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT05316129 |
| Follicle Stimulating Hormone Receptor T Cells | DRUG | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT05316129 |
| Zymosan | BIOLOGICAL | Phase EARLY_PHASE1 | Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04674306 |
| α-lactalbumin vaccine | BIOLOGICAL | Phase EARLY_PHASE1 | Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04674306 |